-
Why ReShape Lifesciences Stock Is Soaring Today: Key Drivers Behind Weight-Loss Company's Surge
Tuesday, June 3, 2025 - 12:54pm | 506ReShape Lifesciences (NASDAQ:RSLS) stock is trending up on Tuesday. Here’s what investors need to know. The premier physician-led weight loss and metabolic health solutions company’s Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in...
-
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Thursday, April 17, 2025 - 4:43pm | 702Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....
-
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Friday, August 9, 2024 - 4:03pm | 554Eli Lilly And Co (NYSE:LLY) reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion. Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago. Zepbound sales reached $1.24 billion, up from $...
-
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Thursday, July 18, 2024 - 4:59pm | 744GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted...
-
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Thursday, May 2, 2024 - 5:48am | 716Novo Nordisk A/S (NYSE:NVO) is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase comes despite supply constraints and competition from Eli Lilly & Co. (NYSE:LLY). What Happened: The Danish pharmaceutical company is now shipping more...
-
Tesla Investor Ross Gerber Backs Ozempic's Potential To Reduce Monthly Food Expenses — Less Eating, More Saving
Wednesday, March 20, 2024 - 4:20am | 779Ross Gerber, a prominent Tesla investor, has suggested that using Ozempic could lead to significant cost savings. What Happened: Gerber took to X (formerly Twitter) to share his thoughts on the potential financial benefits of using Ozempic, a weight-loss drug developed by Novo Nordisk A/S (NYSE:NVO...
-
Here's Why ReShape Life Sciences Has An Opportunity To See A Big Short Squeeze
Monday, June 28, 2021 - 1:00pm | 424ReShape Life Sciences Inc (NASDAQ: RSLS) shares are trading higher Monday after hedge fund Armistice Capital reported it had a 50% ownership stake in the company. The stock was trending throughout the day on social media sites such as StockTwits. The stock trades with a small float of 500,000...